| | plate bound OKT3 (1 ng/mL) | CD8+CD45RA+CCR7+ T (∼31% vs. ∼14%) | reduction of residual tumor cells in vitro (8% vs. 25%) | |
| | increased proportion of IFN-γ+ cells (∼30% vs. ∼20%) |
| | increased proportion of CD107+ cells (∼50% vs. ∼35%) |
| | significantly prolongs mouse survival |
| | |
| | | CD8+ T cells (∼80% vs. ∼70%, Day 11) | considerable in vitro cytotoxicity | |
| | CD8+CD45RA+CD62L+ naive T cells (∼55% vs. ∼40%, Day 5) | similar IFN-γ, IL2 and TNF-α secretion levels |
| | CD8+CD45RA−CD62L+ central memory T cells (∼70% vs. ∼50%, Day 11) | considerable in vivo lysis capacity |
| | CD45RA−CD62L− effector memory T cells (∼25% vs. ∼45%, Day 11) | higher long-term survival rates in vivo xenograft tumor model |